- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
November 08, 2024
From Benzinga
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
From Benzinga
Why Is AstraZeneca Stock Sinking On Tuesday?
November 05, 2024
From Benzinga
From Benzinga
3 Magnificent Stocks Under $100 to Buy in November
November 03, 2024
From Motley Fool
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
October 31, 2024
From Motley Fool
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
October 25, 2024
From Benzinga
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
October 24, 2024
From Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
October 11, 2024
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
From Motley Fool
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
October 07, 2024
From Benzinga
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
October 07, 2024
From Benzinga
US Stocks Open Lower; Dow Tumbles Over 150 Points
October 07, 2024
From Benzinga
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
October 07, 2024
From Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
October 03, 2024
From Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
From Benzinga
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
From Benzinga
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
September 23, 2024
From Benzinga
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
From Benzinga
From Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
From Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
From Benzinga
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
September 10, 2024
From Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
From Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
From Benzinga
3 Market-Beating Stocks to Buy for Less Than $100
September 06, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.